Cargando…

Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial

BACKGROUND: In ALTER 1202, anlotinib prolonged the progression-free survival (PFS) and overall survival (OS) of patients with relapsed small cell lung cancer (SCLC). The aim of this study was to explore the effect of front-line thoracic radiotherapy (RT) on the benefits of anlotinib as a third-line-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Cheng, Ying, Li, Kai, Shi, Jianhua, Liu, Ying, Wu, Lin, Han, Baohui, Chen, Gongyan, He, Jianxing, Wang, Jie, Qin, Haifeng, Li, Xiaoling, Hamaji, Masatsugu, Park, Henry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512470/ https://www.ncbi.nlm.nih.gov/pubmed/34733629 http://dx.doi.org/10.21037/tlcr-21-632

Ejemplares similares

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
por: Cheng, Ying, et al.
Publicado: (2021)

Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study
por: Liu, Ying, et al.
Publicado: (2021)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
por: Cheng, Ying, et al.
Publicado: (2020)

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
por: Zhao, Yizhuo, et al.
Publicado: (2022)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Physics in Pisa 1202-1938: a survey
por: Barcaro, Umberto, et al.
Publicado: (1987)

Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

MicroRNA-1202 plays a vital role in osteoarthritis via KCNQ1OT1 has-miR-1202-ETS1 regulatory pathway
por: Liu, Changzeng, et al.
Publicado: (2020)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report
por: Guan, Yun, et al.
Publicado: (2022)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
por: Cai, Ruoxue, et al.
Publicado: (2023)

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial
por: Shi, Jianhua, et al.
Publicado: (2021)

Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment
por: Kong, Cheng, et al.
Publicado: (2023)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy
por: Guo, Lu, et al.
Publicado: (2021)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

Indolent stage IVA thymic malignancies managed with multimodality treatments
por: Hamaji, Masatsugu
Publicado: (2020)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

1202. It’s a Confidence Scheme—Transmission-based Precautions in the Ambulatory Setting
por: McQuaide, Colleen, et al.
Publicado: (2019)

1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
por: Serio, Alisa W, et al.
Publicado: (2020)

Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
por: Edahiro, Yoko, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

1202. Chagas Disease Awareness in a Hispanic Community of the Greater New Orleans Area
por: Hincapie, Marcela, et al.
Publicado: (2021)

P1202: NOVEL METHODS FOR THE IDENTIFICATION OF A RARE DISEASE, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)
por: Broome, Catherine M, et al.
Publicado: (2023)

Multiple mutations in the EGFR gene in lung cancer is rare but should not be forgettable
por: Miyata, Ryo, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
por: Gong, Jinhong, et al.
Publicado: (2021)

OA12.02. CAM utilization among underserved patients in a safety-net hospital
por: Gardiner, P
Publicado: (2012)

MA12.02 Factors Associated with Severe COVID-19 Infections in Lung Cancer Patients
por: Ganti, A.K., et al.
Publicado: (2021)

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
por: Han, Dong, et al.
Publicado: (2022)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study
por: He, Zelai, et al.
Publicado: (2021)

A novel ABCD1 G1202A mutation in a Chinese patient with pure adrenomyeloneuropathy and literature review
por: Zhang, Yu, et al.
Publicado: (2020)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lt7t709s99to474pbp67ontnh1